Northern Trust Corp Sells 7,602 Shares of Pacira BioSciences, Inc. $PCRX

Northern Trust Corp lessened its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 1.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 609,289 shares of the company’s stock after selling 7,602 shares during the quarter. Northern Trust Corp owned 1.32% of Pacira BioSciences worth $15,141,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC bought a new stake in shares of Pacira BioSciences in the first quarter valued at about $277,000. ProShare Advisors LLC boosted its position in shares of Pacira BioSciences by 30.2% in the fourth quarter. ProShare Advisors LLC now owns 16,003 shares of the company’s stock valued at $301,000 after acquiring an additional 3,710 shares during the period. GAMMA Investing LLC boosted its position in shares of Pacira BioSciences by 112.8% in the first quarter. GAMMA Investing LLC now owns 3,694 shares of the company’s stock valued at $92,000 after acquiring an additional 1,958 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Pacira BioSciences by 3.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company’s stock valued at $491,000 after acquiring an additional 794 shares during the period. Finally, Public Employees Retirement System of Ohio boosted its position in shares of Pacira BioSciences by 21,458.4% in the fourth quarter. Public Employees Retirement System of Ohio now owns 91,192 shares of the company’s stock valued at $1,718,000 after acquiring an additional 90,769 shares during the period. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

Shares of PCRX stock opened at $27.18 on Thursday. The company has a quick ratio of 1.91, a current ratio of 2.38 and a debt-to-equity ratio of 0.50. Pacira BioSciences, Inc. has a twelve month low of $12.61 and a twelve month high of $27.64. The company has a market cap of $1.22 billion, a P/E ratio of -9.78 and a beta of 0.42. The business has a fifty day simple moving average of $23.85 and a 200 day simple moving average of $24.58.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.01. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.The business had revenue of $181.10 million during the quarter, compared to the consensus estimate of $183.11 million. During the same period in the prior year, the company earned $0.96 EPS. Pacira BioSciences’s revenue for the quarter was up 1.7% on a year-over-year basis. Pacira BioSciences has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Pacira BioSciences, Inc. will post 2.41 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Zacks Research raised shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. Needham & Company LLC decreased their price target on Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Truist Financial upgraded Pacira BioSciences from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research report on Friday, July 25th. Finally, Wall Street Zen upgraded Pacira BioSciences from a “hold” rating to a “buy” rating in a research report on Friday, June 6th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Pacira BioSciences currently has a consensus rating of “Moderate Buy” and an average price target of $30.83.

Insider Buying and Selling at Pacira BioSciences

In related news, Director Marcelo Bigal sold 4,912 shares of the company’s stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $23.67, for a total transaction of $116,267.04. Following the completion of the sale, the director directly owned 11,393 shares in the company, valued at $269,672.31. This represents a 30.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.40% of the stock is currently owned by corporate insiders.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.